Autoinflammatory & rare systemic diseases
Treatment Approaches to Macrophage Activation Syndrome in Real Life and Priorities for Future Research: Results From the International METAPHOR Project
Authors' conclusion
MAS management remains highly heterogeneous worldwide.
Study context
- Population
- Physicians treating macrophage activation syndrome (MAS), recruited through PReS/PRINTO and Histiocyte Society networks (October to December 2023)physicians from 64 countries
- Participants
- 287 physicians
- Outcome
- Real-life therapeutic strategies for MAS
Methodological detailsinternational web-based survey, anonymous, descriptive analysis
- International web-based survey
- Anonymous
- Descriptive analysis
Main finding
As reported in the abstract
First-line MAS therapy
GC, particularly IV methylprednisolone, first-line across all MAS subtypes; as monotherapy
44%
Observational data: associations, not effects.
Original publication
Treatment Approaches to Macrophage Activation Syndrome in Real Life and Priorities for Future Research: Results From the International METAPHOR Project. Arthritis Rheumatol. Published 21 September 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →